Today: 19 April 2026
Subscribe
Browse Category

NASDAQ:MMYT 9 January 2026 - 6 March 2026

MakeMyTrip to Buy Flamingo Transworld Stake as India Holiday Package Travel Grows

MakeMyTrip to Buy Flamingo Transworld Stake as India Holiday Package Travel Grows

MakeMyTrip said Thursday it will acquire a majority stake in Flamingo Transworld, a regional tour operator, with no price disclosed and deal closing pending. Flamingo operates mainly in Gujarat, Maharashtra, Rajasthan, and Madhya Pradesh through 51 offices. MakeMyTrip’s hotels and packages revenue rose 9.7% last quarter to $161.4 million, while air ticketing fell. Net profit for the quarter dropped to $7.3 million from $27.1 million.
6 March 2026
·
Booking (BKNG) stock price slips as March split and dividend dates tighten the calendar

Booking (BKNG) stock price slips as March split and dividend dates tighten the calendar

Booking Holdings shares fell 0.26% to $4,239.35 Friday as the company announced a 25-for-1 stock split, with new shares distributed after April 2. The board declared a $10.50 per share dividend payable March 31. Executives reported lower average daily rates and shorter stays in the U.S. Travel stocks broadly declined, with Expedia and TripAdvisor also closing lower.
28 February 2026
····
Booking Holdings (BKNG) stock slips as Booking.com expands Navan tie-up ahead of Feb. 18 results

Booking Holdings (BKNG) stock slips as Booking.com expands Navan tie-up ahead of Feb. 18 results

Booking Holdings shares slipped 0.25% to $5,150.90 Thursday, bucking gains in broader U.S. indexes and sector peers like Expedia. Trading volume reached about 220,000 shares. The company set February 18 for its fourth-quarter and full-year results release. Navan announced an expanded API integration with Booking.com to offer more lodging options for business travelers.
23 January 2026
······
MakeMyTrip stock slides 4.5% in U.S. trade as investors turn to Jan. 22 earnings

MakeMyTrip stock slides 4.5% in U.S. trade as investors turn to Jan. 22 earnings

MakeMyTrip shares fell 4.5% to $78.78 in Friday afternoon trading, underperforming U.S.-listed travel peers. The stock hit a session high of $83.42 before sliding, with no new company updates ahead of its expected Jan. 22 earnings. Trading volume reached about 577,000 shares by mid-session. The drop puts MakeMyTrip near its lowest levels since early January.
9 January 2026
··

Stock Market Today

  • ATI Share Price Surges 262% in One Year, But Valuation Flags Overvaluation
    April 18, 2026, 9:38 PM EDT. Shares of ATI have surged 261.9% over the past year to close at $164.66, fueled by interest in its Aerospace & Defense role. Despite strong gains, ATI scores 0 out of 6 on valuation checks. A Discounted Cash Flow (DCF) model estimates ATI's intrinsic value at approximately $142.92 per share, suggesting the stock is overvalued by 15.2%. The DCF uses projected free cash flows rising from $362.7 million to $1.19 billion by 2035. Investors are questioning whether current prices reflect fundamentals or if sentiment has outpaced growth prospects. Price-to-Earnings (P/E) ratios remain a quick gauge of value, linking share price to current earnings, but must account for growth and risk outlooks. ATI's elevated valuation hints at potential risks despite stellar price momentum.

Latest article

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

18 April 2026
Definium Therapeutics shares rose to $22.68 after Stifel and Piper Sandler initiated coverage with Buy ratings, citing late-stage trials of DT120, an LSD-based tablet for anxiety and depression. The company will host an investor day April 22 in New York to discuss upcoming Phase 3 data. DT120 is in four pivotal studies, with top-line results expected through 2026. Johnson & Johnson and Compass Pathways are advancing rival clinic-based psychiatric drugs.
Go toTop